title: Significance of target cell infection and natural killer cells in the anti-tumor effects of bacillus Calmette-Guerin in murine bladder cancer.
abstract: Although intravesical instillation of bacillus Calmette-Guerin (BCG) is a clinically well-recognized therapy for bladder carcinoma in situ and recurrence prophylaxis, these mechanisms have not been fully understood. We studied the effects of BCG infection (Connaught strain) on target cancer cells and host immune systems in murine bladder cancer. The bladder cancer cell line, MB49, was used in C57/BL6 mice in vivo and in vitro. In vitro cytotoxicities against the cancer cell line were measured by 24-h 51Cr release assay. For effector cells, spleen mononuclear cells were obtained from mice injected intraperitoneally with BCG or BCG-infected irradiated MB49 cells. Although BCG infection of cancer cells did not affect the proliferation speed in vitro, the mice injected subcutaneously with BCG-infected MB49 cells survived significantly longer than those given untreated cancer cells. The mice surviving without tumor growth after injection of BCG-infected cancer cells could not reject a second injection of intact MB49 cells. In vitro cytotoxicity was enhanced by BCG infection of target cancer cells, but not by immunizing the mice with BCG from which effector cells were obtained. Moreover, cytotoxicity disappeared by depleting natural killer (NK) cells from effector cells. Although in vitro cytotoxicity was increased by immunizing the mice with BCG-infected irradiated MB49 cells, survival did not improve in these mice. These results suggest that a major part of BCG's anti-tumor effects can be attributed to the elimination of BCG-infected cancer cells by NK cells.
authors.affiliation: Department of Urology, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan.
authors.forename: Teppei
authors.initials: T
authors.lastname: Sonoda
authors.forename: Kazunobu
authors.initials: K
authors.lastname: Sugimura
authors.forename: Shin-Ichi
authors.initials: S
authors.lastname: Ikemoto
authors.forename: Hidenori
authors.initials: H
authors.lastname: Kawashima
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Nakatani
mesh_terms: D000818:Animals; D001500:BCG Vaccine / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy* / Q000276:immunology / Q000382:microbiology; D045744:Cell Line, Tumor; D003602:Cytotoxicity, Immunologic; D007694:Killer Cells, Natural / Q000276:immunology*; D008212:Lymphocyte Depletion; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009374:Neoplasms, Experimental; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000382:microbiology
chemical_list: D001500:BCG Vaccine